One dead, dozens injured from earthquake in Peru
June 16 (UPI) -- At least one person was killed and and dozens injured in Peru after an earthquake shook the coastline near its capital city of Lima.
According to a series of posts on X from Peru's National Emergency Center, or COEN, and National Institute of Civil Defense, or INDECI, the 6.1-magnitude quake sent 36 people to hospitals around Lima.
Eleven of the injured have reportedly since been discharged, while the condition and nature of the injuries suffered by the 25 still hospitalized is unclear.
The death was reported to have occurred in Lima's Independencia district.
Fourteen health facilities were also damaged, as were 13 educational institutions. An unspecified number of homes were reported to have collapsed in the Mi Perú district in the province of Callao.
Peruvian President Dina Boluarte Zegarra's office announced Sunday that the coastline was being monitored after the incident, which the United States Geological Survey measured as a 5.6-magnitude earthquake, with an epicenter about 14 miles southwest of Callao. A 3.6-magnitude aftershock was also reported in Callao province.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
21 minutes ago
- Miami Herald
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs
June 17 (UPI) --Eli Lilly and Company said Tuesday it will buy out Boston-based Verve Therapeutics Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs. Indianapolis-based Eli Lilly announced its definitive agreement to acquire Verge, a gene-editing startup, for up to $1.3 billion at $10.50 a share -- a premium of 67.5% at last closing -- with the goal to boost Verve's budding pipeline of medicine designed to target and treat a wide-range of cardiovascular-related health issues. "Lilly is eager to welcome our Verve colleagues to Lilly and continue the development of these promising potential new medicines aimed at improving outcomes for patients with cardiovascular disease and addressing the significant unmet medical need in this space," said Ruth Gimeno, Lilly's group VP for diabetes and metabolic research and development. Under the agreement terms, the transaction will not be subject to any financing conditions and will include a nearly $1 billion upfront payout plus a further $300 million based on certain clinical milestones. The deal is expected to close by this year's third quarter subject to conditions. Verve's medical treatment program, according to a Gimeno, could "shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment." Meanwhile, stock shares in Verve jumped 76% to over $11 in premarket trading Tuesday morning while Lilly stock value fell 1%. A years-long study from 2010-2022 released in November revealed how the number of dead via cardiovascular disease had surged among adults ages 25 to 64 living in rural areas. Verve uses a next gen type of gene editing which erases and rewrites a specific gene letter. Lilly's Gimeno says the Verve-102 program, which is currently in its Phase 1b clinal trial study and fast-tracked for FDA approval, "has the potential" to be the first "in vivo" gene editing therapy deployed to treat a broad population of patients seeking treatment for cardiac issues. 102 may be utilized for patients seeking treatment for heterozygous familial hypercholesterolemia (HeFH), which is a subset of ASCVD affecting 1 in 250 people. On Tuesday, Verve's chief noted how in just seven years that the Verve team had progressed three in vivo gene editing products with two currently in clinics. "Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," said Verve Therapeutics co-founder and CEO Dr. Sekar Kathiresan. Copyright 2025 UPI News Corporation. All Rights Reserved.
Miami Herald
7 hours ago
- Miami Herald
Kraft Heinz to remove all artificial dyes from its foods
June 17 (UPI) -- The Kraft Heinz company announced Tuesday it has begun the process to fully drop any artificial dyes being used in its foods in the United States. What this may visually mean for its colorful powdered mix creations like Kool-Aid and Jell-O is unclear, but the company says its goal is to have all Food, Drug and Cosmetic colors out of its product portfolio by the end of 2027. "The vast majority of our products use natural or no colors," said Kraft Heinz North America President Pedro Navio in a press release, "and we've been on a journey to reduce our use of [Food, Drug and Cosmetic] colors across the remainder of our portfolio." Navio also pointed out that the company had already taken out "artificial colors, preservatives, and flavors" from its Kraft Mac & Cheese, and that its Heinz Tomato Ketchup has never had artificial dyes. The company further noted in the release that almost 90% of Kraft Heinz's American products are already free of such colors and is" mobilizing a team" to help rid the dyes from the rest of its edibles. The move comes after an April announcement from the U.S. Food and Drug Administration and Department of Health and Human Services that it will take measures to remove all petroleum-based synthetic dyes from American foods. "Above all, we are focused on providing nutritious, affordable, and great-tasting food for Americans and this is a privilege we don't take lightly," added Navio. Copyright 2025 UPI News Corporation. All Rights Reserved.
UPI
7 hours ago
- UPI
Kraft Heinz to remove all artificial dyes from its foods
June 17 (UPI) -- The Kraft Heinz company announced Tuesday it has begun the process to fully drop any artificial dyes being used in its foods in the United States. What this may visually mean for its colorful powdered mix creations like Kool-Aid and Jell-O is unclear, but the company says its goal is to have all Food, Drug and Cosmetic colors out of its product portfolio by the end of 2027. "The vast majority of our products use natural or no colors," said Kraft Heinz North America President Pedro Navio in a press release, "and we've been on a journey to reduce our use of [Food, Drug and Cosmetic] colors across the remainder of our portfolio." Navio also pointed out that the company had already taken out "artificial colors, preservatives, and flavors" from its Kraft Mac & Cheese, and that its Heinz Tomato Ketchup has never had artificial dyes. The company further noted in the release that almost 90% of Kraft Heinz's American products are already free of such colors and is" mobilizing a team" to help rid the dyes from the rest of its edibles. The move comes after an April announcement from the U.S. Food and Drug Administration and Department of Health and Human Services that it will take measures to remove all petroleum-based synthetic dyes from American foods. "Above all, we are focused on providing nutritious, affordable, and great-tasting food for Americans and this is a privilege we don't take lightly," added Navio.
